TCB-2 is a hallucinogen discovered in 2006 by Thomas McLean working in the lab of Prof. David Nichols at Purdue University where it was named 2C-BCB. It is a conformationally-restricted derivative of the phenethylamine 2C-B also a hallucinogen and acts as a potent agonist for the 5-HT2A and 5-HT2C receptors with a Ki of 0.26nM at the human 5-HT2A receptor.
This page contains content from the copyrighted Wikipedia article "TCB-2"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
